We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.
- Authors
Leigh, P Nigel; Swash, Michael; Iwasaki, Yasuo; Ludolph, Albert; Meininger, Vincent; Miller, Robert G; Mitsumoto, Hiroshi; Shaw, Pamela; Tashiro, Kunio; Van Den Berg, Leonard
- Abstract
In November 2002, an advisory board meeting was convened by Novartis Pharma to provide recommendations and rationale for clinical trials designed to evaluate new treatments, such as TCH346, for amyotrophic lateral sclerosis (ALS). In terms of selecting appropriate outcome measures, the panel recommended the use of the ALS Functional Rating Scale (ALSFRS-R) to measure primary endpoints. A review of other key issues in this area including regional variations in the epidemiology, diagnosis and management of ALS, defining patient populations and doses of trial medication, and accommodating the likelihood of co-medication with pre-existing treatment in trial design, are discussed.
- Publication
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, Vol 5, Issue 2, p84
- ISSN
1466-0822
- Publication type
Journal Article
- DOI
10.1080/14660820410020187